Clinical data | |
---|---|
Routes of administration | By mouth |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H24FN5OS |
Molar mass | 449.55 gยทmol |
3D model (JSmol) | |
SMILES
| |
InChI
|
NNI-351 is an orally active inhibitor of DYRK1ATooltip dual specificity tyrosine-phosphorylation-regulated kinase 1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.
See also
References
- ^ "Research programme: Psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight".
- Froestl W, Muhs A, Pfeifer A (2013). "Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes". J. Alzheimer's Dis. 33 (3): 547โ658. doi:10.3233/JAD-2012-121537. PMID 23042218. S2CID 34896894.
- "Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome". GlobeNewswire News Room. GlobalNewsWire. 1 June 2022. Retrieved 15 January 2023.
External links
- NNI-351 - NeuroNascent, Inc
- NNI-351 - AdisInsight
- Methods and pharmaceutical compositions for treating down syndrome (patent)
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |